Dr Reddy's completes acquisition of product portfolio from Teva

Dr Reddy’s Laboratories Ltd on August 3, 2016 announced that it successfully completed the previously announced acquisition of eight abbreviated new drug applications (ANDAs) in the US from Teva Pharmaceutical Industries Ltd and an affiliate of Allergan Plc. The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan’s generics business.

The portfolio being acquired is a mix of six ANDAs pending approval, one approved ANDA and one ANDA with tentative approval, and comprises complex generic products across diverse dosage forms. The combined sales of the branded versions of the products in the US is approximately $ 3.5 billion MAT for the most recent twelve months ending in June 2016, according to IMS Health.